689 related articles for article (PubMed ID: 17804716)
1. Gamma-secretase inhibitor prevents Notch3 activation and reduces proliferation in human lung cancers.
Konishi J; Kawaguchi KS; Vo H; Haruki N; Gonzalez A; Carbone DP; Dang TP
Cancer Res; 2007 Sep; 67(17):8051-7. PubMed ID: 17804716
[TBL] [Abstract][Full Text] [Related]
2. Gamma-secretase inhibitors target tumor-initiating cells in a mouse model of ERBB2 breast cancer.
Kondratyev M; Kreso A; Hallett RM; Girgis-Gabardo A; Barcelon ME; Ilieva D; Ware C; Majumder PK; Hassell JA
Oncogene; 2012 Jan; 31(1):93-103. PubMed ID: 21666715
[TBL] [Abstract][Full Text] [Related]
3. Notch signaling contributes to lung cancer clonogenic capacity in vitro but may be circumvented in tumorigenesis in vivo.
Osanyingbemi-Obidi J; Dobromilskaya I; Illei PB; Hann CL; Rudin CM
Mol Cancer Res; 2011 Dec; 9(12):1746-54. PubMed ID: 21994468
[TBL] [Abstract][Full Text] [Related]
4. The gamma secretase inhibitor MRK-003 attenuates pancreatic cancer growth in preclinical models.
Mizuma M; Rasheed ZA; Yabuuchi S; Omura N; Campbell NR; de Wilde RF; De Oliveira E; Zhang Q; Puig O; Matsui W; Hidalgo M; Maitra A; Rajeshkumar NV
Mol Cancer Ther; 2012 Sep; 11(9):1999-2009. PubMed ID: 22752426
[TBL] [Abstract][Full Text] [Related]
5. Evodiamine suppresses Notch3 signaling in lung tumorigenesis via direct binding to γ-secretases.
Yang X; Zhang Y; Huang Y; Wang Y; Qi X; Su T; Lu L
Phytomedicine; 2020 Mar; 68():153176. PubMed ID: 32045841
[TBL] [Abstract][Full Text] [Related]
6. Combined antitumor effect of γ-secretase inhibitor and ABT-737 in Notch-expressing non-small cell lung cancer.
Sakakibara-Konishi J; Ikezawa Y; Oizumi S; Kikuchi J; Kikuchi E; Mizugaki H; Kinoshita I; Dosaka-Akita H; Nishimura M
Int J Clin Oncol; 2017 Apr; 22(2):257-268. PubMed ID: 27816990
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of role of Notch3 signaling pathway in human lung cancer cells.
Hassan WA; Yoshida R; Kudoh S; Motooka Y; Ito T
J Cancer Res Clin Oncol; 2016 May; 142(5):981-93. PubMed ID: 26838758
[TBL] [Abstract][Full Text] [Related]
8. Blocking the NOTCH pathway can inhibit the growth of CD133-positive A549 cells and sensitize to chemotherapy.
Liu J; Mao Z; Huang J; Xie S; Liu T; Mao Z
Biochem Biophys Res Commun; 2014 Feb; 444(4):670-5. PubMed ID: 24502949
[TBL] [Abstract][Full Text] [Related]
9. Downregulation of Notch pathway by a gamma-secretase inhibitor attenuates AKT/mammalian target of rapamycin signaling and glucose uptake in an ERBB2 transgenic breast cancer model.
Efferson CL; Winkelmann CT; Ware C; Sullivan T; Giampaoli S; Tammam J; Patel S; Mesiti G; Reilly JF; Gibson RE; Buser C; Yeatman T; Coppola D; Winter C; Clark EA; Draetta GF; Strack PR; Majumder PK
Cancer Res; 2010 Mar; 70(6):2476-84. PubMed ID: 20197467
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of gamma-secretase activity impedes uterine serous carcinoma growth in a human xenograft model.
Groeneweg JW; Hall TR; Zhang L; Kim M; Byron VF; Tambouret R; Sathayanrayanan S; Foster R; Rueda BR; Growdon WB
Gynecol Oncol; 2014 Jun; 133(3):607-15. PubMed ID: 24667249
[TBL] [Abstract][Full Text] [Related]
11. Gamma-secretase inhibition attenuates oxaliplatin-induced apoptosis through increased Mcl-1 and/or Bcl-xL in human colon cancer cells.
Timme CR; Gruidl M; Yeatman TJ
Apoptosis; 2013 Oct; 18(10):1163-74. PubMed ID: 23887890
[TBL] [Abstract][Full Text] [Related]
12. Notch signaling promotes growth and invasion in uveal melanoma.
Asnaghi L; Ebrahimi KB; Schreck KC; Bar EE; Coonfield ML; Bell WR; Handa J; Merbs SL; Harbour JW; Eberhart CG
Clin Cancer Res; 2012 Feb; 18(3):654-65. PubMed ID: 22228632
[TBL] [Abstract][Full Text] [Related]
13. Notch signaling activation in pediatric low-grade astrocytoma.
Brandt WD; Schreck KC; Bar EE; Taylor I; Marchionni L; Raabe E; Eberhart CG; Rodriguez FJ
J Neuropathol Exp Neurol; 2015 Feb; 74(2):121-31. PubMed ID: 25575134
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of Notch and HIF enhances the antitumor effect of radiation in Notch expressing lung cancer.
Ikezawa Y; Sakakibara-Konishi J; Mizugaki H; Oizumi S; Nishimura M
Int J Clin Oncol; 2017 Feb; 22(1):59-69. PubMed ID: 27553958
[TBL] [Abstract][Full Text] [Related]
15. Quinomycin A targets Notch signaling pathway in pancreatic cancer stem cells.
Ponnurangam S; Dandawate PR; Dhar A; Tawfik OW; Parab RR; Mishra PD; Ranadive P; Sharma R; Mahajan G; Umar S; Weir SJ; Sugumar A; Jensen RA; Padhye SB; Balakrishnan A; Anant S; Subramaniam D
Oncotarget; 2016 Jan; 7(3):3217-32. PubMed ID: 26673007
[TBL] [Abstract][Full Text] [Related]
16. γ-Secretase inhibitor enhances antitumour effect of radiation in Notch-expressing lung cancer.
Mizugaki H; Sakakibara-Konishi J; Ikezawa Y; Kikuchi J; Kikuchi E; Oizumi S; Dang TP; Nishimura M
Br J Cancer; 2012 Jun; 106(12):1953-9. PubMed ID: 22596234
[TBL] [Abstract][Full Text] [Related]
17. A high Notch pathway activation predicts response to γ secretase inhibitors in proneural subtype of glioma tumor-initiating cells.
Saito N; Fu J; Zheng S; Yao J; Wang S; Liu DD; Yuan Y; Sulman EP; Lang FF; Colman H; Verhaak RG; Yung WK; Koul D
Stem Cells; 2014 Jan; 32(1):301-12. PubMed ID: 24038660
[TBL] [Abstract][Full Text] [Related]
18. Down-regulation of the Notch pathway mediated by a gamma-secretase inhibitor induces anti-tumour effects in mouse models of T-cell leukaemia.
Tammam J; Ware C; Efferson C; O'Neil J; Rao S; Qu X; Gorenstein J; Angagaw M; Kim H; Kenific C; Kunii K; Leach KJ; Nikov G; Zhao J; Dai X; Hardwick J; Scott M; Winter C; Bristow L; Elbi C; Reilly JF; Look T; Draetta G; Van der Ploeg L; Kohl NE; Strack PR; Majumder PK
Br J Pharmacol; 2009 Nov; 158(5):1183-95. PubMed ID: 19775282
[TBL] [Abstract][Full Text] [Related]
19. MRK003, a γ-secretase inhibitor exhibits promising in vitro pre-clinical activity in multiple myeloma and non-Hodgkin's lymphoma.
Ramakrishnan V; Ansell S; Haug J; Grote D; Kimlinger T; Stenson M; Timm M; Wellik L; Halling T; Rajkumar SV; Kumar S
Leukemia; 2012 Feb; 26(2):340-8. PubMed ID: 21826062
[TBL] [Abstract][Full Text] [Related]
20. Notch3 overexpression as potential therapeutic target in advanced stage chemoresistant ovarian cancer.
Rahman MT; Nakayama K; Rahman M; Katagiri H; Katagiri A; Ishibashi T; Ishikawa M; Iida K; Nakayama S; Otsuki Y; Miyazaki K
Am J Clin Pathol; 2012 Oct; 138(4):535-44. PubMed ID: 23010708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
